Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-020873
Filing Date
2025-02-14
Accepted
2025-02-14 13:25:08
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10226
2 EX-99.1 ck0001669811-ex99_1.htm EX-99.1 8007
  Complete submission text file 0000950170-25-020873.txt   19968
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
AVENUE THERAPEUTICS, INC. (Subject) CIK: 0001644963 (see all company filings)

EIN.: 474113275 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90144 | Film No.: 25626164
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201
Business Address 100 CRESCENT COURT SUITE 1620 DALLAS TX 75201 214-364-2883
Ikarian Capital, LLC (Filed by) CIK: 0001778253 (see all company filings)

EIN.: 473466768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G